Pfizer Stock: Court Ruling Clouds Positive Momentum

Pfizer shares gained 0.9 percent on Wednesday in New York trading, closing at $25.98 after reaching an intraday high of $26.17. Investor interest remained strong with over one million shares changing hands, though the stock continues to trade significantly below its 52-week high of $31.54 recorded in July 2024. To reclaim this peak, the share price would need to surge by more than 21 percent. Currently, Pfizer sits approximately 6 percent above its 52-week low of $24.49 established in November 2024. Despite these fluctuations, financial projections for the pharmaceutical giant appear promising, with analysts assigning an average price target of $30.40 and forecasting earnings of $2.95 per share for 2025. The company is expected to release its next quarterly results on May 6, 2025.

Patent Dispute Threatens Financial Outlook

A legal setback could potentially undermine Pfizer's market position and financial projections. On Wednesday, a German court in Düsseldorf ruled that Pfizer and development partner BioNTech violated a COVID-19 vaccine patent held by Moderna. The court order requires both companies to disclose revenue generated through the patent infringement and provide Moderna with appropriate compensation. While the exact payment amount remains undetermined pending further legal proceedings, Pfizer and BioNTech retain the option to appeal the decision. This unexpected development introduces uncertainty that could impact investor sentiment despite otherwise favorable financial forecasts.

Ad

Fresh Pfizer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Source StockWorld